Build 'VetOncoAI'—a SaaS platform that uses AI to optimize oral chemotherapy dosing, monitor treatment efficacy, and predict remission likelihood for canine lymphoma. The platform would: 1) Deploy computer vision to analyze pet wearables (e.g., FitBark) and home videos for symptoms (e.g., 'Lethargy detected: 90% confidence'); 2) Provide a 'Dosing Optimization Dashboard' showing real-time adjustments (e.g., 'Reduce Laverdia® dose by 15%'); 3) Integrate with veterinary EHR APIs (e.g., IDEXX) to auto-generate FDA-compliant reports; 4) Offer a 'Cost Predictor' to estimate treatment expenses and connect owners to pet insurance/funding programs.

Veterinarians, pet owners, and animal pharmaceutical companies Canine lymphoma treatment has historically relied on injectable chemotherapies, which are expensive ($5K–$10K per cycle), require frequent vet visits, and cause significant stress for pets and owners. Oral treatments are rare due to bioavailability challenges, and no AI-driven platforms exist to optimize dosing or predict treatment outcomes for animals. The global veterinary oncology market is $1.2B+, with 50% of pet owners opting for euthanasia due to cost and treatment complexity. The operational cost of manual dosing adjustments and follow-ups averages $300 per visit.